A study comparing the effects of taking Phalaghrita orally and giving Uttarbasti therapy in treating female infertility caused by problems in the uterus and ovaries.

A Clinical Comparative Evaluation Of Phalaghrita Paan And Uttarbasti In The Management Of Kshetra - Beeja Dushtijanya Bandhyatva With Special Reference To Utero - Ovarian Factors - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104334

Enrollment

Registered

2026-02-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O268- Other specified pregnancy relatedconditions

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Married women with age between 23 to 40 years. 2. Diagnosed or undiagnosed patients of primary and secondary infertility. 3. Patients coming with uterine factor abnormalities. 4. Patients having ovulatory dysfunction. 5. Patients willing to participate and provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Women of age less than 23 and above 40 years. 2. Patients having any systemic disorders like Hypertension,Diabetes,Tuberculosis etc. 3. Patients with congenital and structural uterine abnormalities like septum,fibroid,polyp, endometriosis, adenomyosis etc. 4. Patients with active and chronic inflammatory disease eg any urogenital infection,STD,Hep B Surface Antigen(HBsAg),VDRL,HCV etc. 5. Patients having malignancy of the reproductive tract. 6. Patients taking Oral contraceptive pills, Progesterone only pills etc.

Design outcomes

Primary

Measure	Time frame
To establish the comparative efficacy of Phalaghrita Paan and Uttarbasti in the management of Kshetra - Beeja dushtijanya Bandhyatva with special reference to Utero-Ovarian factors.Timepoint: Duration of trial - 3 Months Follow up- 3 Follow ups with trial drug and 1 Follow up without trial drug.	—

Secondary

Measure	Time frame
1.To study etiopathogenesis of Kshetra-Beeja Dushtijanya Bandhyatva with special reference to utero-ovarian factors. 2.To screen and compile all the available literature on Kshetra-Beeja dushtijanya bandhyatva and its correlation with modern science. 3.To clinically evaluate the efficacy of Phalaghrita Paan in the management of Kshetra-Beeja dushtijanya Bandhyatva with special reference to utero-ovarian factors. 4.To clinically evaluate the efficacy of Phalaghrita uttarbasti in the management of Kshetra-Beeja dushtijanya Bandhyatva with special reference to utero-ovarian factors. 5.To compare the clinical efficacy of treatment given in both the trial groups. 6.To provide comparatively safe, cost effective, non - hormonal and non - surgical treatment for infertile patients. 7.To study the complications of trial drug if any, during and after the procedure.Timepoint: Follow up 3 Follow ups with trial drug and 1 Follow up without trial drug. First Follow up- After cessation of first menstrual cycle Second Follow up- After cessation of second menstrual cycle Third Follow up - After cessation of third menstrual cycle Fourth Follow up -After cessation of fourth menstrual cycle(without any medication).	—

Measure

Time frame

1.To study etiopathogenesis of Kshetra-Beeja Dushtijanya Bandhyatva with special reference to utero-ovarian factors. 2.To screen and compile all the available literature on Kshetra-Beeja dushtijanya bandhyatva and its correlation with modern science. 3.To clinically evaluate the efficacy of Phalaghrita Paan in the management of Kshetra-Beeja dushtijanya Bandhyatva with special reference to utero-ovarian factors. 4.To clinically evaluate the efficacy of Phalaghrita uttarbasti in the management of Kshetra-Beeja dushtijanya Bandhyatva with special reference to utero-ovarian factors. 5.To compare the clinical efficacy of treatment given in both the trial groups. 6.To provide comparatively safe, cost effective, non - hormonal and non - surgical treatment for infertile patients. 7.To study the complications of trial drug if any, during and after the procedure.Timepoint: Follow up 3 Follow ups with trial drug and 1 Follow up without trial drug. First Follow up- After cessation of first menstrual cycle Second Follow up- After cessation of second menstrual cycle Third Follow up - After cessation of third menstrual cycle Fourth Follow up -After cessation of fourth menstrual cycle(without any medication).

—

Countries

India

Contacts

Public ContactProf Shashi Sharma

State Ayurvedic College and Hospital, Lucknow Uttar Pradesh.

shashi.chd98@gmail.com8795545443

Outcome results